CN101822679B - 盐酸头孢吡肟组合药物 - Google Patents
盐酸头孢吡肟组合药物 Download PDFInfo
- Publication number
- CN101822679B CN101822679B CN201010103846XA CN201010103846A CN101822679B CN 101822679 B CN101822679 B CN 101822679B CN 201010103846X A CN201010103846X A CN 201010103846XA CN 201010103846 A CN201010103846 A CN 201010103846A CN 101822679 B CN101822679 B CN 101822679B
- Authority
- CN
- China
- Prior art keywords
- cefepime hydrochloride
- cefepime
- hydrochloride
- combined medicament
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960000927 cefepime hydrochloride Drugs 0.000 title claims abstract description 127
- 239000003814 drug Substances 0.000 title claims abstract description 70
- LRAJHPGSGBRUJN-OMIVUECESA-N cefepime hydrochloride Chemical compound O.Cl.[Cl-].S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 LRAJHPGSGBRUJN-OMIVUECESA-N 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 claims abstract description 38
- 238000002347 injection Methods 0.000 claims abstract description 31
- 239000007924 injection Substances 0.000 claims abstract description 31
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 claims description 154
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 40
- 239000007788 liquid Substances 0.000 claims description 35
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 32
- 229960002100 cefepime Drugs 0.000 claims description 32
- 206010035664 Pneumonia Diseases 0.000 claims description 21
- 238000005516 engineering process Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 20
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 17
- 235000003969 glutathione Nutrition 0.000 claims description 17
- 229960003180 glutathione Drugs 0.000 claims description 17
- 238000000108 ultra-filtration Methods 0.000 claims description 17
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 16
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 16
- 229930003268 Vitamin C Natural products 0.000 claims description 16
- 229960004194 lidocaine Drugs 0.000 claims description 16
- 235000019154 vitamin C Nutrition 0.000 claims description 16
- 239000011718 vitamin C Substances 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 206010022000 influenza Diseases 0.000 claims description 11
- 238000005374 membrane filtration Methods 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 2
- 208000003455 anaphylaxis Diseases 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 208000001297 phlebitis Diseases 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 231100000234 hepatic damage Toxicity 0.000 abstract 1
- 230000008818 liver damage Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 25
- 208000015181 infectious disease Diseases 0.000 description 25
- 238000010172 mouse model Methods 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 241000191967 Staphylococcus aureus Species 0.000 description 10
- 241000193998 Streptococcus pneumoniae Species 0.000 description 10
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 7
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 6
- 102000009338 Gastric Mucins Human genes 0.000 description 6
- 108010009066 Gastric Mucins Proteins 0.000 description 6
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000011082 depyrogenation Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- OJMNTWPPFNMOCJ-CFOLLTDRSA-M cefamandole sodium Chemical compound [Na+].CN1N=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OJMNTWPPFNMOCJ-CFOLLTDRSA-M 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 239000008141 laxative Substances 0.000 description 5
- 231100000668 minimum lethal dose Toxicity 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 230000001543 purgative effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002040 relaxant effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000013112 stability test Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- HVFLCNVBZFFHBT-FKULVZFESA-N (6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-FKULVZFESA-N 0.000 description 1
- JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940021422 maxipime Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
项目 | A菌种感染组死亡率% | B菌种感染组死亡率% | C菌种感染组死亡率% | D菌种感染组死亡率% | 药物热反应率% | 室温存一年含量下降率% | 胃及肝不良反应率% |
不给药治疗 | 100 | 100 | 100 | 100 | -- | -- | -- |
20mg/kg注射用盐酸头孢吡肟给药 | 50 | 60 | 60 | 40 | 20 | 30 | 10 |
本发明药20mk/kg给药 | 20 | 30 | 20 | 10 | 0 | 10 | 0 |
备注 |
项目 | A菌种感染组死亡率% | B菌种感染组死亡率% | C菌种感染组死亡率% | D菌种感染组死亡率% | 药物热反应率% | 室温存一年含量下降率% | 胃及肝不良反应率% |
不给药治疗 | 100 | 100 | 100 | 100 | -- | -- | -- |
20mg/kg盐酸头孢吡肟给药 | 60 | 60 | 60 | 50 | 20 | 30 | 10 |
本发明药物20mk/kg给药 | 20 | 30 | 20 | 10 | 0 | 6 | 0 |
备注 |
项目 | A菌种感染组死亡率% | B菌种感染组死亡率% | C菌种感染组死亡率% | D菌种感染组死亡率% | 药物热反应率% | 室温存一年含量下降率% | 胃及肝不良反应率% |
不给药治疗 | 100 | 100 | 100 | 100 | -- | -- | -- |
20mg/kg盐酸头孢吡肟给药 | 60 | 50 | 50 | 60 | 20 | 25 | 10 |
本发明药物20mk/kg给药 | 20 | 30 | 20 | 10 | 0 | 4 | 0 |
备注 |
项目 | A菌种感染组死亡率% | B菌种感染组死亡率% | C菌种感染组死亡率% | D菌种感染组死亡率% | 药物热反应率% | 室温存一年含量下降率% | 胃及肝不良反应率% |
不给药治疗 | 100 | 100 | 100 | 100 | -- | -- | -- |
20mg/kg盐酸头孢吡肟给药 | 60 | 70 | 60 | 50 | 20 | 27 | 10 |
本发明药物20mk/kg给药 | 20 | 30 | 20 | 10 | 0 | 5 | 0 |
备注 |
项目 | A菌种感染组死亡率% | B菌种感染组死亡率% | C菌种感染组死亡率% | D菌种感染组死亡率% | 药物热反应率% | 室温存一年含量下降率% | 胃及肝不良反应率% |
不给药治疗 | 100 | 100 | 100 | 100 | -- | -- | -- |
20mg/kg盐酸头孢吡肟给药 | 60 | 60 | 60 | 50 | 20 | 30 | 10 |
本发明药物20mk/kg给药 | 20 | 30 | 20 | 10 | 0 | 10 | 0 |
备注 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010103846XA CN101822679B (zh) | 2010-02-02 | 2010-02-02 | 盐酸头孢吡肟组合药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010103846XA CN101822679B (zh) | 2010-02-02 | 2010-02-02 | 盐酸头孢吡肟组合药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101822679A CN101822679A (zh) | 2010-09-08 |
CN101822679B true CN101822679B (zh) | 2012-05-30 |
Family
ID=42686983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010103846XA Active CN101822679B (zh) | 2010-02-02 | 2010-02-02 | 盐酸头孢吡肟组合药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101822679B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103908671A (zh) * | 2014-01-21 | 2014-07-09 | 邓学峰 | 一种前列地尔的组合药物 |
CN103768069A (zh) * | 2014-01-22 | 2014-05-07 | 邓学峰 | 一种头孢他啶的组合药物 |
CN103751123A (zh) * | 2014-01-22 | 2014-04-30 | 邓学峰 | 一种头孢唑林的组合药物 |
CN111956597A (zh) * | 2020-08-28 | 2020-11-20 | 上海欣峰制药有限公司 | 一种注射用盐酸头孢吡肟及其制备方法 |
CN114042048B (zh) * | 2021-10-29 | 2023-02-28 | 海南海灵化学制药有限公司 | 一种注射用盐酸头孢吡肟的制备工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101229128A (zh) * | 2007-08-14 | 2008-07-30 | 山东罗欣药业股份有限公司 | 一种盐酸头孢吡肟粉针剂及其制备方法 |
CN101332188A (zh) * | 2008-07-11 | 2008-12-31 | 海南数尔药物研究有限公司 | 用超微粉碎技术制备粉针剂的方法及制备的产品 |
-
2010
- 2010-02-02 CN CN201010103846XA patent/CN101822679B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101229128A (zh) * | 2007-08-14 | 2008-07-30 | 山东罗欣药业股份有限公司 | 一种盐酸头孢吡肟粉针剂及其制备方法 |
CN101332188A (zh) * | 2008-07-11 | 2008-12-31 | 海南数尔药物研究有限公司 | 用超微粉碎技术制备粉针剂的方法及制备的产品 |
Non-Patent Citations (2)
Title |
---|
赵振寰,等.还原型谷胱甘肽的临床应用.《齐鲁医学杂志》.2006,第21卷(第2期),第185-186页. * |
韦运杰,等.利多卡因与布比卡因抑菌作用的临床研究.《临床麻醉学杂志》.2006,第22卷(第9期),第683-685页. * |
Also Published As
Publication number | Publication date |
---|---|
CN101822679A (zh) | 2010-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101822679B (zh) | 盐酸头孢吡肟组合药物 | |
CN104323987B (zh) | 一种乙酰甲喹注射液及其制备方法 | |
CN101991640A (zh) | 一种含十大功劳的中药组合物的制备方法及其应用 | |
CN101874808A (zh) | 阿奇霉素组合药物 | |
CN101822686B (zh) | 硫酸头孢匹罗组合药物 | |
CN101317904B (zh) | 乌梅提取物在制备抗畜禽病毒药物中的用途 | |
CN101822678B (zh) | 头孢孟多酯钠组合药物 | |
CN102614294B (zh) | 一种复方阿莫西林混悬注射剂及其制备方法 | |
CN101850105B (zh) | 头孢呋辛钠组合药物 | |
CN101849948A (zh) | 头孢呋辛酯组合药物 | |
CN107714678B (zh) | 紫檀芪在制备mcr-1酶抑制剂中的应用 | |
CN101850104B (zh) | 盐酸克林霉素组合药物 | |
CN102920656A (zh) | 一种莫西沙星纳米乳及其制备方法 | |
CN103142990A (zh) | 一种治疗畜禽细菌性疾病的药物及其制备方法 | |
CN102793713A (zh) | 盐酸林可霉素-硫酸大观霉素注射液及其制备方法 | |
CN101822680B (zh) | 一种头孢匹胺组合药物 | |
CN104000778A (zh) | 利巴韦林注射液及其制备方法 | |
KR102252009B1 (ko) | 비자나무 잎 추출물을 포함하는 항바이러스용 또는 살균용 조성물 | |
CN101467999A (zh) | 一种盐酸小檗碱复方制剂 | |
CN101822681A (zh) | 一种头孢西丁钠组合药物 | |
CN101850103B (zh) | 克林霉素磷酸酯组合药物 | |
CN101797374A (zh) | 用于治疗禽类呼吸系统疾病的复方盐酸米诺环素可溶性粉 | |
CN103908674A (zh) | 一种利福霉素钠的组合药物 | |
CN115317468B (zh) | 萜品-4-醇在制备抗炎药物或抗呼吸道合胞病毒药物中的应用 | |
EP3733176A1 (en) | Composition comprising piperacillin, pharmaceutical preparation thereof and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100908 Assignee: JIANGSU FANGSHENG PHARMACEUTICAL CO.,LTD. Assignor: Deng Xuefeng Contract record no.: 2015530000071 Denomination of invention: Cefepime hydrochloride combined medicament Granted publication date: 20120530 License type: Common License Record date: 20151127 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231105 Address after: 334600 Industrial Plot 186, Block C, Luyang Industrial Park, Guangfeng Economic Development Zone, Guangfeng District, Shangrao City, Jiangxi Province Patentee after: Jiangxi Yuetu Medical Equipment Co.,Ltd. Address before: 334600 Yongfeng Street, 156 Lulin Avenue, Guangfeng County, Jiangxi Province Patentee before: Deng Xuefeng |